Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Director comp.
Appointed director
|
|
23andMe Holding Co.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/09/2022 |
8-K
| Investor presentation |
| 08/18/2022 |
8-K
| Quarterly results |
| 01/18/2022 |
8-K
| Investor presentation|
Docs:
|
"11.9M1 1M 825,000 500,000 366,000 219,000 500,000 REGENERON ALL OF US MILLION VETERAN PROGRAM FINNGEN UK BIOBANK DECODE GENETICS GENOMICS ENGLAND",
"23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe elects for royalty option as GSK advances immuno-oncology antibody collaboration program targeting CD96 into development Company will discuss at its R&D Day event today at 8:00 a.m. Pacific Time SUNNYVALE, CA - January 18, 2022 - 23andMe Holding Co. , a leading consumer genetics and therapeutics company, today provided an update on its collaboration with GlaxoSmithKline plc . GSK has elected to exercise its option to extend the exclusive target discovery period of the ongoing collaboration with 23andMe for ..." |
|
|
|